Functional impact of usual interstitial pneumonia pattern in interstitial lung diseases
References
- Maher TM. Interstitial Lung Disease: A Review. JAMA. 2024;331(19):1655–65.
- Spagnolo P, Guler SA, Chaudhuri N, et al. Global epidemiology and burden of interstitial lung disease. Lancet Respir Med. 2025;13(8):739–55.
- Batra K, Butt Y, Gokaslan T, Burguete D, Glazer C, Torrealba JR. Pathology and radiology correlation of idiopathic interstitial pneumonias. Hum Pathol. 2018;72:1–17.
- Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383(10):958–68.
- Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.
- Lynch DA, Travis WD, Müller NL, et al. Idiopathic Interstitial Pneumonias: CT Features. Radiology. 2005;236(1):10–21.
- Tonelli R, Smit MR, Castaniere I, et al. Quantitative CT-analysis of over aerated lung tissue and correlation with fibrosis extent in patients with idiopathic pulmonary fibrosis. Respir Res. 2024;25(1):359.
- Kumar DP. Assessment and Follow-Up of Interstitial Lung Disease. Indian J Rheumatol. 2021;16(1S):S69–78.
- Chetta A, Marangio E, Olivieri D. Pulmonary Function Testing in Interstitial Lung Diseases. Respiration. 2004;71(3):209–13.
- Pereira CAC, Cordero S, Resende AC. Progressive fibrotic interstitial lung disease. J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia. 2023;49(5):e20230098.
- Richeldi L, Bois RM du, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071–82.
- King TE, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2083–92.
- Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–27.
- Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.
- Kolb M, Flaherty KR, Silva RS, et al. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics. Adv Ther. 2023;40(12):5536–46.
- Case AH, Johnson P. Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res [Internet]. 2017 [cited 2026 Feb 7];4(1) Available from: https://bmjopenrespres.bmj.com/content/4/1/e000192.
- Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518–28.
- Roman J. Progress in Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025;211(10):1751–2.
- Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.
- Mondoni M, Varone F, Luppi F, et al. Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study. Lung. 2025;203(1):77.
DOI: https://doi.org/10.62838/amsm-2026-0025 | Journal eISSN: 2668-7763 (formerly 2247-6113) | Journal ISSN: 2668-7755
Language: English
Page range: 195 - 199
Submitted on: Mar 21, 2026
Accepted on: Jul 23, 2026
Published online: Sep 30, 2026
Published in print: Sep 1, 2026
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2026 Georgian-Vlăduț Doncean, Dariana-Elena Pătrîntașu, Ionuț-Alexandru Rența, Eugenia-Corina Budin, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.